Gerresheimer's Gx G-Fix adapter integrates prefilled glass syringes with polymer-based autoinjector devices.
Gerresheimer's patent-pending Gx G-Fix adapter integrates prefilled glass syringes with polymer-based autoinjector devices. Most autoinjectors contain two main modules: the injector itself and the prefilled syringe. The modules are combined in one assembly, but combining two different materials is a challenge, because glass prefilled syringes have different tolerance requirements than plastic devices. The plastic adapter attaches to the syringe shoulder and provides a precisely defined interface to the device.
In the past, the high dimensional tolerance of the glass syringe only permitted limited control of the injection needle’s position in the front opening of the autoinjector. Because Gx G-Fix is specifically adapted to the autoinjector, it allows accurate needle positioning and improves control of the injection process. The adapter also protects the syringe against breakage. Conventional products coupled the syringe with the finger flange. When triggered, the structurally sensitive flange is subjected to a lot of pressure and can easily break. With Gx G-Fix, however, attaching the syringe at the sturdier shoulder minimizes the risk of breakage.
The Gx G-Fix is assembled in conjunction with ready-to-fill syringe processing at the syringe manufacturer’s facility. Device integration and RNS positioning with Gx G-Fix can be used individually or in combination in the autoinjector. Plastic syringes can also be easily fitted with the adapter. Autoinjectors with Gx G-Fix are therefore suitable for both plastic and glass syringes and can be used for a variety of drugs. No changes to the customer’s filling station are necessary.
Source: Gerresheimer
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
INTERPHEX 2025: Use of Walk-In Chambers for Bio/Pharma Development and Manufacturing
April 2nd 2025Sitting down with the PharmTech Group at INTERPHEX 2025, Christopher Murphy, director of Global Business Development and Service Customer Support at Environmental Specialties, discusses the design and critical role of walk-in chambers in the bio/pharmaceutical industry.